• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Neem’s Hill

3.45 SEK-0.86 %22.7. klo 18.29
Less than 1K followers

NEEMS B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.86 %
-4.96 %
-15.65 %
+2.68 %
-31.27 %
+74.24 %
-11.13 %
-88.58 %
-90.84 %

Neem’s Hill is a Swedish company that develops and markets medical technology based on electrochemotherapy for the treatment of cancer. The company offers systems and solutions to clinics in oncology and veterinary medicine and has operations in international markets, including India and Southeast Asia. The company was founded in 2015 and is headquartered in Lund, Sweden.

Read more
Market cap
90.44M SEK
Turnover
18.98K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
11.8.
2026

Interim report Q2'26

27.10.
2026

Interim report Q3'26

23.2.
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release13.07.2026 klo 09.45

Scandinavian ChemoTech AB changes name to Neem's Hill AB

Neem’s Hill
Regulatory press release01.07.2026 klo 13.46

ChemoTech's TSE Reports 97% Complete Remission and Stronger Than Expected Clinical Results in Equine

Neem’s Hill
Press release01.07.2026 klo 09.30

ChemoTech: Clinical Publication on TSE Therapy for the Treatment of Equine Sarcoids to Be Presented During ECVS

Neem’s Hill

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release25.06.2026 klo 10.47

ChemoTech Enters Strategic Partnership with the University of Copenhagen's Veterinary Hospitals

Neem’s Hill
Regulatory press release02.06.2026 klo 18.51

Corr. of press release: ChemoTech secures 6 MSEK Growth Loan from a Swedish Financial Institution

Neem’s Hill
Regulatory press release02.06.2026 klo 17.16

Scandinavian ChemoTech secures SEK 6 million Growth Loan from a larger Swedish Financial Institution

Neem’s Hill
Regulatory press release19.05.2026 klo 16.13

ChemoTech announces outcome of the directed issue

Neem’s Hill
Regulatory press release28.04.2026 klo 09.30

Scandinavian ChemoTech AB (publ) publishes Interim report Q1 2026

Neem’s Hill
Press release07.04.2026 klo 15.40

ChemoTech's Proposed Strategic Changes Accepted by Nasdaq First North

Neem’s Hill
Press release02.04.2026 klo 09.45

(RETRANS) Scandinavian ChemoTech Starts 2026 Strong with Best First Quarter in Company History

Neem’s Hill
Regulatory press release01.04.2026 klo 17.50

Scandinavian ChemoTech Starts 2026 Strong with Best First Quarter in Company History

Neem’s Hill
Regulatory press release31.03.2026 klo 09.15

ChemoTech proposes expanded business activities, name change & received proposal on directed issue

Neem’s Hill
Regulatory press release17.03.2026 klo 14.37

ChemoTech's subsidiary Scandinavian Meditech Achieves Full CDSCO MD-15 Import License in India

Neem’s Hill
Press release19.02.2026 klo 10.43

Redeye: Scandinavian ChemoTech (Q4 Review): Seasonal softness, intact growth case

Neem’s Hill
Press release19.02.2026 klo 09.45

ChemoTech: (RETRANS) Clinical Study on TSE in Equine Sarcoid Mgmt. to be presented at the upcoming ECVS Meeting.

Neem’s Hill
Regulatory press release18.02.2026 klo 21.50

ChemoTech: Clinical Study on TSE in Equine Sarcoid Management to be presented at the upcoming ECVS Meeting

Neem’s Hill
Regulatory press release17.02.2026 klo 09.30

Scandinavian ChemoTech AB (publ) publishes Year-end report 2025

Neem’s Hill
Press release05.01.2026 klo 09.30

New Year's Letter to Shareholders in Scandinavian ChemoTech - Reflecting on 2025

Neem’s Hill
Press release05.12.2025 klo 09.49

(RETRANS) ChemoTech's Animal Care Announces First U.S. Order from Leading Equine Clinic in Kentucky

Neem’s Hill
Regulatory press release04.12.2025 klo 20.12

ChemoTech's Animal Care Announces First U.S. Order from Leading Equine Clinic in Kentucky

Neem’s Hill